规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
靶点 |
CDK4 (IC50 = 2 nM); CDK6 (IC50 = 10 nM)
|
---|---|
体外研究 (In Vitro) |
体外活性:Abemaciclib(以前称为 LY2835219)是一种有效、选择性、口服的 CDK4(细胞周期蛋白依赖性激酶)和 CDK6 双重抑制剂,在无细胞测定中 IC50 分别为 2 nM 和 10 nM。 LY2835219 特异性抑制 CDK4 和 6,从而抑制 G1 早期视网膜母细胞瘤 (Rb) 蛋白磷酸化。抑制 Rb 磷酸化可阻止 CDK 介导的 G1-S 相变,从而将细胞周期阻滞在 G1 期,抑制 DNA 合成并抑制癌细胞生长。丝氨酸/苏氨酸激酶 CDK4/6 的过度表达可导致细胞周期失调,如某些类型的癌症中所见。激酶测定:将细胞 (5 × 103) 铺在 96 孔板中。第二天将细胞处理 24 至 48 小时,然后根据制造商的说明和发光板读数器,通过 Caspase-Glo-3/7 测定法评估 caspase-3 活性。细胞测定:将细胞接种到 96 孔板中,使其粘附过夜,并用 DMSO 对照 (0.1% v/v) 或指定化合物处理 72 小时。根据制造商的说明,使用细胞计数试剂盒测定细胞活力和增殖。使用 CompuSyn 确定 LY2835219 和 mTOR 抑制剂之间的相互作用。组合指数 (CI) 值为 1 表示药物相互作用相加,而 CI < 1 表示协同作用,CI > 1 表示拮抗作用。
|
体内研究 (In Vivo) |
LY2835219 使 BBB 流出饱和,未结合血浆 IC50 约为 95 nM。 LY2835219-MsOH 在大脑中的剂量百分比为 0.5–3.9%。在皮下和颅内人胶质母细胞瘤模型 (U87MG) 中,LY2835219-MsOH 作为单一药物以及与替莫唑胺联合使用,均以剂量依赖性方式抑制肿瘤生长。
|
动物实验 |
Female C57BL/6 mice
50 mg/kg i.p. |
参考文献 |
分子式 |
C28H36F2N8O3S
|
---|---|
分子量 |
602.7
|
精确质量 |
602.26
|
元素分析 |
C, 55.80; H, 6.02; F, 6.30; N, 18.59; O, 7.96; S, 5.32
|
CAS号 |
1231930-82-7
|
相关CAS号 |
Abemaciclib;1231929-97-7
|
外观&性状 |
Solid powder
|
SMILES |
CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F.CS(=O)(=O)O
|
InChi Key |
NCJPFQPEVDHJAZ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C27H32F2N8.CH4O3S/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26;1-5(2,3)4/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34);1H3,(H,2,3,4)
|
化学名 |
N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine;methanesulfonic acid
|
别名 |
Abemaciclib; LY-2835219 mesylate; LY2835219; LY 2835219; Abemaciclib mesylate
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2 mg/mL (3.32 mM) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2 mg/mL (3.32 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: Water: 100 mg/mL (~165.9 mM) Solubility in Formulation 7: 25 mg/mL (41.48 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Solubility in Formulation 8: 12.5 mg/mL (20.74 mM) in 0.5% HEC (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6592 mL | 8.2960 mL | 16.5920 mL | |
5 mM | 0.3318 mL | 1.6592 mL | 3.3184 mL | |
10 mM | 0.1659 mL | 0.8296 mL | 1.6592 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Effects of LY2835219 on RB pathway and intracellular signaling.Oncotarget.2016 Mar 22;7(12):14803-13. th> |
---|
Combined effect of LY2835219 and mTOR inhibitorsin vitro.Oncotarget.2016 Mar 22;7(12):14803-13. td> |
LY2835219 and mTOR inhibitor combination in HNSCC xenograft tumor model.Oncotarget.2016 Mar 22;7(12):14803-13. td> |
Antitumor activity of LY2835219 in HNSCC xenograft tumor model.Oncotarget.2016 Mar 22;7(12):14803-13. th> |
---|
Effects of CDK4/6 inhibitor LY2835219 on cell growth in HNSCC.Oncotarget.2016 Mar 22;7(12):14803-13. td> |
Effects of LY2835219 on cell proliferation and cell cycle in HNSCC.Oncotarget.2016 Mar 22;7(12):14803-13. td> |